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Supplementary Information for “A subset of NSAIDs lower 
amyloidogenic Aβ42 independent of COX activity”   
 
 
Methods for Supplementary Information 
Antibodies. 
Monoclonal antibodies 5A3 and 1G7 recognizing non-overlapping epitopes of APP between 
residues 380-665, polyclonal antibody CT15 against the C-terminal 15 amino acid residues of 
APP, and monoclonal antibody 26D6 against amino acid residues 1-12 of the Aβ sequence have 
been described 1-3.  The monoclonal antibody against COX-2 was purchased from BD 
Transduction Laboratories, the polyclonal antibody against COX-1 (M-20) was purchased from 
Santa Cruz Biotechnology. 
Measurements of Prostaglandin E2 levels in cell culture media 
To determine PGE2 levels in CHO cells and mouse fibroblasts after NSAID treatment, 2 x 105 
cells were seeded per well in 24 well plates and treated overnight with the indicated 
concentrations of NSAIDs.  Medium was replaced and COX-2 expression was induced with 
100 nM PMA for 8h in the presence of NSAIDs or vehicle.  PGE2 levels were then analyzed 
with a commercial enzyme immunoassay (Amersham Pharmacia Biotech).  To compare 
Prostaglandin E2 secretion in COX-1 -/-, COX-2 -/- fibroblast versus littermate control 
fibroblasts, 2.5 x 105 cells were seeded per well in 24 well plates and grown for 24 h. Medium 
was changed and cells were incubated in the presence or absence of 100 nM PMA for 8 h. 
PGE2 levels in culture medium were then quantified by enzyme immunoassay as above. 
Analysis of APP processing after NSAID treatment 
Expression of holo-APP and APP CTFs was examined by Western blot analysis with antibody 
CT-15.  β-CTF levels were investigated by immunoprecipitation with antibody 26D6 
recognizing the N-terminus of Aβ, followed by Western-blotting with antibody CT-15.  APPs 
and APPs-α secretion was analyzed by Western blot analysis of culture medium with antibodies 
5A3/1G7 or 26D6.  APP turnover was investigated by metabolic labeling in CHO cells with 
150 µCi [35S]-methionine for 15 min and cold chase for up to 4h.  Cell lysates were 
immunoprecipitated with antibody CT-15, subjected to SDS-PAGE and analyzed by phosphor 
imaging.  APP surface expression and internalization was measured as described 1.  In brief, 
iodinated 1G7 antibody (~3-6 µCi/µg) was applied to confluent layers of CHO cells in binding 
medium (DMEM, 0.2% BSA, 20 mM HEPES) and incubated at 37oC for 30 min.  After 
incubation, cells were rapidly chilled on ice, and the reaction was quenched by the addition of 
ice-cold binding medium.  Chilled cells were washed multiple times with ice-cold Dulbecco’s 
phosphate-buffered saline to eliminate unbound antibody.  Residual antibody bound to surface 
APP was then detached from cell surfaces by two 5 min washes with ice-cold PBS, pH 2.0.  
Cells remaining in the culture dish were lysed in 0.2 M NaOH.  Acid-labile and acid-resistant 
APP antibody counts were measured by γ-counting.  The ratio of acid-resistant to acid-labile 
counts provided a measure of the internalized versus cell surface pools of APP. 
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Table 1 Summary of results with sulindac sulfide in various cell lines 
Cell line Transfected gene(s) ≥50% reduction in Aβ42 
levels (80-100 µM) 
CHO cell lines 
 APP751 wild type + 
 APP751 wild type and PS-1 wild type + 
 APP751 wild type and PS-1 M146L mutation + 
 APP751 wild type and PS-1 C410Y mutation + 
 APP751 wild type and PS-2 wild type + 
 APP751 wild type and PS-2 M239V mutation + 
 APP751 KM670/671 NL “Swedish” mutation + 
 APP751 with V717F “Indiana” mutation + 
Neuroglioma cell lines 
HS683 APP695 wild type + 
HS683 APP695 wild type and mutant PS-1 M146L mutation + 
H4 APP695 wild type + 
HEK293 cell lines 
 APP695 wild type + 
Mouse fibroblast cell lines 
 COX-1 +/+, COX-2 +/+ control fibroblasts + 
 COX-1 -/-, COX-2 -/- fibroblasts + 
 COX-1 -/-, COX-2 -/- fibroblasts and PS-1 M146L 
mutation 
+ 
 
 
Table 2 Summary of effects on Aβ42 levels by various NSAIDs in cultured cells 
NSAID COX specificity Highest concentration tested (µM) Aβ42 reduction* 
sulindac sulfide non-selective 200 + 
ibuprofen non-selective 1000 + 
indomethacin non-selective 400 + 
naproxen non-selective 400 - 
sulindac sulfone no COX activity 400 - 
aspirin COX-1 specific 3000 - 
SC-560 COX-1 specific 100 - 
meloxicam COX-2 
preferential 
100 - 
celecoxib COX-2 specific 20 - 
* Reduction at least 50% in two or more cell lines. 
 
  
3 
 
Figure 1 Prostaglandin E2 levels in cell culture media after NSAID treatment.  a, PGE2 levels 
after NSAID treatment in CHO cells stably transfected with both APP751 and the PS1 M146L 
mutation (APP WT/ PS1 M146L).  NSAID treatment dramatically reduced PGE2 levels in 
culture media as expected.  Treatment with 25 µM naproxen reduced PGE2 production to 
undetectable levels.  b. PGE2 levels in mouse fibroblasts after NSAID treatment.  Mouse 
fibroblasts showed high levels of PGE2 secretion after PMA stimulation.  Consistent with the 
results on CHO cells, NSAID treatment strongly reduced PGE2 levels in culture media.  Results 
show one representative experiment performed in duplicate (mean ± s.d.). 
 
 
 
Figure 2 COX-1 -/-, COX-2 -/- fibroblasts are devoid of COX protein expression and 
enzymatic activity.  a, Western blot analysis of COX protein expression in COX-1 -/-, COX-2 -
/- fibroblasts and littermate control fibroblasts.  The control fibroblasts showed expression of 
COX-1 and COX-2 protein whereas in the knockout fibroblasts, COX-1 and COX-2 proteins 
were absent.  b, COX-1 +/+, COX-2 +/+ fibroblasts showed a threefold induction of PGE2 
levels after stimulation with PMA.  Consistent with previously published data 4 PGE2 levels in 
COX-1 -/-, COX-2 -/- fibroblast were undetectable even under induced conditions.  Results 
show one representative experiment performed in triplicate (mean ± s.d.). 
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Figure 3 Analysis of APP processing in APP WT CHO cells after sulindac sulfide treatment.  
a, Steady-state APP levels detected by western blotting.  No change was seen in either the 
levels of full length APP, α-CTFs or β-CTFs after sulindac sulfide treatment.  Western blotting 
with antibody CT-15 detects full length APP and predominantly α-CTF while 
immunoprecipitation with antibody 26D6 followed by blotting with CT-15 detects β-CTF. b, 
Secretion of APPs and APPs-α was unaffected by sulindac sulfide treatment as examined by 
Western blot analysis of culture medium with antibodies antibodies 5A3/1G7 or 26D6.  
Antibody 26D6 against amino acid residues 1-12 of the Aβ sequence detects only APPs-α.  c, 
APP turnover in the presence of sulindac sulfide.  All values were normalized to the signal 
obtained at the beginning of the chase period (top panel).  Representative autoradiogram is 
shown in the bottom panel.  APP turnover was unaffected by sulindac sulfide.  Similar results 
were obtained in HS683 neuroglioma cells (data not shown).  d, APP internalization, expressed 
as the ratio of cell surface APP versus internalized APP, was unchanged after sulindac sulfide 
treatment.  The mean ± s.d. of two independent experiments performed in duplicate is shown. 
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Figure 4 Scattergram of Aβ40 and Aβ42 levels in brain of Tg2576 mice after short-term 
ibuprofen treatment by ELISA.  Three-month-old female mice were orally dosed with ibuprofen 
(n=15), naproxen (n=7) or mock treated (n=18).  On average, treatment with ibuprofen induced 
a 39% decrease in brain levels of SDS-soluble Aβ42 without any changes in Aβ40.  Consistent 
with our cell culture experiments, naproxen treatment did not induce any changes in Aβ40 and 
Aβ42 levels.  Note that x- and y-axes represent Aβ40 and Aβ42 levels in pmol/gm brain tissue, 
respectively. 
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